Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


Research and Development
Drug Candidates
Patent Portfolio
Clinical Development
Abstracts and Scientific Information
Professional Services
Educational Resources

 

Chronic Fatigue Syndrome

Note: The Company's clinical trials are not necessarily indicative of future clinical trials or approvals.

AMP 511
An Open-Label Study of Poly I: Poly C12U (Ampligen®) in Patients with Severely Debilitating Chronic Fatigue Syndrome (CFS) / Myalgic Encephalomyelitis (ME).

AMP 516
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Poly I: Poly C12U (Ampligen®) 400 MG IV Twice Weekly Versus Placebo in Patients with Severely Debilitating Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME).
 

 
Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.